Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on November 7, 2018. The filing serves to announce the company's financial results for the quarter ended September 30, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
No material changes or comparative financial data versus the prior period are disclosed in the body of this Form 8-K. The document solely acts as a notification that the quarterly results have been announced.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the text provided.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release) referenced in this filing.
- Confirm the company name is Aerpio Pharmaceuticals, Inc., as the input metadata incorrectly listed Whitehawk Therapeutics, Inc.
- Review the full press release for any updates on clinical trial progress or pipeline developments not summarized in this 8-K.